About: N-Glycosylation Alteration of Serum and Salivary Immunoglobulin A Is a Possible Biomarker in Oral Mucositis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: N-Glycosylation Alteration of Serum and Salivary Immunoglobulin A Is a Possible Biomarker in Oral Mucositis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	N-Glycosylation Alteration of Serum and Salivary Immunoglobulin A Is a Possible Biomarker in Oral Mucositis
Creator	Hortobágyi, Tibor Tóth, Ferenc Gebri, Enikő Guttman, András Jankovics, Hajnalka Kiss, Attila Kovács, Zsuzsanna Mészáros, Brigitta Simon, Ádám Vonderviszt, Ferenc
source	PMC
abstract	Background: Oral and enteral mucositis due to high-dose cytostatic treatment administered during autologous and allogeneic stem-cell transplantation increases mortality. Salivary secretory immunoglobulin A (sIgA) is a basic pillar of local immunity in the first line of defense. Altered salivary sialoglycoprotein carbohydrates are important in the pathologies in the oral cavity including inflammation, infection and neoplasia. Therefore, we assessed whether changes in the salivary and serum IgA glycosylation correlated with development and severity of oral mucositis. Methods: Using capillary electrophoresis, comparative analysis of serum and salivary IgA total N-glycans was conducted in 8 patients with autologous peripheral stem-cell transplantation (APSCT) at four different stages of transplantation (day −3/−7, 0, +7, +14) and in 10 healthy controls. Results: Fourteen out of the 31 structures identified in serum and 6 out of 38 in saliva showed significant changes upon transplantation compared with the control group. Only serum core fucosylated, sialylated bisecting biantennary glycan (FA2BG2S2) showed significant differences between any two stages of transplantation (day −3/−7 and day +14; p = 0.0279). Conclusion: Our results suggest that changes in the serum IgA total N-glycan profile could serve as a disease-specific biomarker in patients undergoing APSCT, while analysis of salivary IgA N-glycan reflects the effect of APSCT on local immunity.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.3390/jcm9061747
bibo:pmid	32516910
has license	cc-by
sha1sum (hex)	078235b2b2e6168eda0cd3ef80ed1529d59f53de
schema:url	https://doi.org/10.3390/jcm9061747
resource representing a document's title	N-Glycosylation Alteration of Serum and Salivary Immunoglobulin A Is a Possible Biomarker in Oral Mucositis
has PubMed Central identifier	PMC7355945
has PubMed identifier	32516910
schema:publication	J Clin Med
resource representing a document's body	covid:078235b2b2e6168eda0cd3ef80ed1529d59f53de#body_text
is schema:about of	named entity 'CONTROL GROUP' named entity 'TREATMENT' named entity 'HIGH-DOSE' named entity 'SECRETORY IMMUNOGLOBULIN A' named entity 'IS A' named entity 'DISEASE' named entity 'CORRELATED' named entity 'AUTOLOGOUS' named entity 'ALTERED' named entity 'PILLAR' named entity 'RESULTS' named entity 'CONTROLS' named entity 'fucosylated' named entity 'serum' named entity 'autologous' named entity 'sialoglycoprotein' named entity 'infection' named entity 'mucositis' named entity 'inflammation' named entity 'high-dose' named entity 'cytostatic' named entity 'pathologies' named entity 'N-glycan' named entity 'control group' named entity 'N-Glycosylation' named entity 'Oral Mucositis' named entity 'N-glycan' named entity 'BD Biosciences' named entity 'serum' named entity 'antigens' named entity 'oral mucositis' named entity 'N-glycan' named entity 'life-threatening' named entity 'IgA' named entity 'immunosuppressive therapy' named entity 'exoglycosidase' named entity 'mucosal immunity' named entity 'carbohydrate' named entity 'LPS' named entity 'melphalan' named entity 'biochemical' named entity 'glycan' named entity 'diabetes' named entity 'Sigma-Aldrich' named entity 'mucositis' named entity 'oral flora' named entity 'remission' named entity 'principal component analysis' named entity 'malignant' named entity 'remission' named entity 'glycome' named entity 'saliva samples' named entity 'serum' named entity 'saliva' named entity 'N-glycan' named entity 'allogeneic' named entity 'serum' named entity 'IgA' named entity 'N-glycan' named entity 'immunoglobulin' named entity 'saliva samples' named entity 'targeted therapy' named entity 'glycans' named entity 'stem cells' named entity 'Budapest' named entity 'control group' named entity 'crevicular' named entity 'pathogens' named entity 'viruses' named entity 'disease monitoring' named entity 'antibody' named entity 'oral cavity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software